TherapeuticsMD Inc (NASDAQ:TXMD) received a $10.00 price target from analysts at Deutsche Bank AG in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Deutsche Bank AG’s price target points to a potential upside of 76.06% from the company’s previous close.

A number of other analysts have also recently commented on the company. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research report on Friday, July 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 price target on shares of TherapeuticsMD in a research report on Friday, July 21st. Finally, Cowen and Company restated an “outperform” rating and issued a $13.00 price target on shares of TherapeuticsMD in a research report on Monday, July 17th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $16.14.

TherapeuticsMD (NASDAQ TXMD) opened at 5.67 on Friday. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The company’s market cap is $1.16 billion. The firm has a 50-day moving average price of $5.43 and a 200 day moving average price of $5.52.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative return on equity of 71.36% and a negative net margin of 530.84%. The business’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.11) earnings per share. Analysts expect that TherapeuticsMD will post ($0.44) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Deutsche Bank AG Reiterates $10.00 Price Target for TherapeuticsMD Inc (NASDAQ:TXMD)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/deutsche-bank-ag-reiterates-10-00-price-target-for-therapeuticsmd-inc-nasdaqtxmd/1471693.html.

Several hedge funds have recently added to or reduced their stakes in the company. Managed Account Services Inc. boosted its stake in TherapeuticsMD by 5.5% in the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after buying an additional 1,000 shares in the last quarter. Amalgamated Bank boosted its stake in TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after buying an additional 1,322 shares in the last quarter. Greenwood Capital Associates LLC boosted its stake in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares in the last quarter. Principal Financial Group Inc. boosted its stake in TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after buying an additional 818 shares in the last quarter. Finally, Traynor Capital Management Inc. boosted its stake in TherapeuticsMD by 14.0% in the second quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after buying an additional 2,799 shares in the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.